| P50 | author | Owen J Sansom | Q37382476 |
| P2093 | author name string | Ross L Cagan | |
| | Erdem Bangi | |
| | Claudio Murgia | |
| | Alexander G S Teague | |
| P2860 | cites work | Cancer genome landscapes | Q22242276 |
| | Hallmarks of Cancer: The Next Generation | Q22252312 |
| | A distinctive DNA damage response in human hematopoietic stem cells reveals an apoptosis-independent role for p53 in self-renewal. | Q51904571 |
| | Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. | Q52423411 |
| | Sequential cancer mutations in cultured human intestinal stem cells. | Q52423597 |
| | Advances in the preclinical testing of cancer therapeutic hypotheses. | Q53264472 |
| | Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus | Q24600932 |
| | Molecular origins of cancer: Molecular basis of colorectal cancer | Q24617331 |
| | Comprehensive molecular characterization of human colon and rectal cancer | Q24630415 |
| | Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 |
| | FoxOs inhibit mTORC1 and activate Akt by inducing the expression of Sestrin3 and Rictor | Q24632191 |
| | mTOR signaling in growth control and disease | Q24634174 |
| | Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers | Q24649562 |
| | MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study | Q27852083 |
| | Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 |
| | The consensus coding sequences of human breast and colorectal cancers | Q27861035 |
| | Targeted gene expression as a means of altering cell fates and generating dominant phenotypes | Q27861039 |
| | The genomic landscapes of human breast and colorectal cancers | Q27861078 |
| | Defining the role of mTOR in cancer | Q28235431 |
| | Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche | Q28239639 |
| | Regulation of SRC family kinases in human cancers | Q28243770 |
| | The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data | Q28266682 |
| | Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal | Q28288215 |
| | Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies | Q28590387 |
| | Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors | Q29618610 |
| | Matrix metalloproteinases: regulators of the tumor microenvironment | Q29619858 |
| | In vivo analysis of compound activity and mechanism of action using epistasis in Drosophila | Q31043762 |
| | Quantifying Drosophila food intake: comparative analysis of current methodology | Q33560845 |
| | PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer | Q33933172 |
| | Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations | Q34153696 |
| | Recent advances in apoptosis, mitochondria and drug resistance in cancer cells | Q34174664 |
| | Clinical development success rates for investigational drugs | Q34396786 |
| | PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors | Q34769343 |
| | mTOR complex 2 targets Akt for proteasomal degradation via phosphorylation at the hydrophobic motif. | Q34800160 |
| | Uncoupling p53 functions in radiation-induced intestinal damage via PUMA and p21. | Q34988091 |
| | Gene expression systems in Drosophila: a synthesis of time and space. | Q35840597 |
| | Prandiology of Drosophila and the CAFE assay. | Q35854804 |
| | Signaling pathways in intestinal development and cancer | Q35912854 |
| | Immune response to bacteria induces dissemination of Ras-activated Drosophila hindgut cells | Q36008282 |
| | Small molecule-induced cytosolic activation of protein kinase Akt rescues ischemia-elicited neuronal death | Q36068891 |
| | Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases | Q36238283 |
| | Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. | Q36716682 |
| | Chemical genetic discovery of targets and anti-targets for cancer polypharmacology | Q36988960 |
| | Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance | Q37036297 |
| | How genetically engineered mouse tumor models provide insights into human cancers | Q37065678 |
| | The Drosophila hindgut lacks constitutively active adult stem cells but proliferates in response to tissue damage | Q37410616 |
| | Drug development in advanced colorectal cancer: challenges and opportunities | Q37428176 |
| | Current progress in targeted therapy for colorectal cancer | Q37654660 |
| | Oncogene-induced cellular senescence | Q37662119 |
| | Preclinical development of molecular-targeted agents for cancer | Q37816960 |
| | Exploring the genomes of cancer cells: progress and promise | Q37857590 |
| | Development of PI3K inhibitors: lessons learned from early clinical trials | Q38080710 |
| | Genetically engineered animal models for in vivo target identification and validation in oncology | Q38084226 |
| | Personalizing oncology: perspectives and prospects | Q38099304 |
| | Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors | Q38205751 |
| | Patient-centric trials for therapeutic development in precision oncology. | Q38607709 |
| | Prospective derivation of a living organoid biobank of colorectal cancer patients. | Q38877277 |
| | Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells | Q39475750 |
| | Antitumor activity and drug interactions of proteasome inhibitor Bortezomib in human high-risk myelodysplastic syndrome cells | Q39567948 |
| | Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway. | Q39568919 |
| | Mutant PIK3CA promotes cell growth and invasion of human cancer cells | Q40410776 |
| | Characterization of the interface between normal and transformed epithelial cells | Q42450915 |
| | Bringing target-matched PI3King from the bench to the clinic | Q42541269 |
| | Tumour biology: senescence in premalignant tumours | Q42802962 |
| | The behaviour of Drosophila adult hindgut stem cells is controlled by Wnt and Hh signalling | Q46106090 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| | Drosophila | Q312154 |
| | colorectal carcinoma | Q25493920 |
| P304 | page(s) | 13615 | |
| P577 | publication date | 2016-11-29 | |
| P1433 | published in | Nature Communications | Q573880 |
| P1476 | title | Functional exploration of colorectal cancer genomes using Drosophila | |
| P478 | volume | 7 | |